Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

MAY 12, 2023

The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.

Development 130

Development Antibody Immune Response Genome 130

Pharmaceutical Technology

JUNE 24, 2022

1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4 Given SARS-CoV-2’s ability to mutate and change its genome, it is hard to say what will be the future variants of the virus. In addition to providing protection against the Omicron BA.1 1 variant of concern.

Vaccine 264

Vaccine Vaccination Antibody Medicine 264

BioTech 365

DECEMBER 3, 2021

Global Research Antibodies Market Drivers 2021-2028 Include Rise In The Availability Of Technologically Advanced Products and a Rise In Proteomics And Genomics Research – ResearchAndMarkets.com Global Research Antibodies Market Drivers 2021-2028 Include Rise In The Availability Of Technologically Advanced Products … Continue reading → (..)

Genome 40

Genome Genomics Antibody Production 40

Drug Discovery Today

FEBRUARY 16, 2021

Celltrion is on track developing a neutralising antibody cocktail with Regdanvimab (CT-P59) tailored to fight against the emerging new variants. CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2.

Antibody 45

Antibody Development Genome Genomics 45

BioSpace

JUNE 7, 2022

Financing rounds will support platforms for tumor-targeting antibodies, genome-scale nucleic and acid imaging. Funding this week went mostly to companies with sophisticated tech platforms.

Genome 73

Genome Genomics Antibody 73

pharmaphorum

MARCH 24, 2022

The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies. The platform uses an artificial intelligence (AI) algorithm to zero in on the genes encoding natural products based on their computationally predicted human target.

Medicine 105

Medicine Genome Genomics Engineer 105

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. CHICAGO , Nov.

DNA 52

DNA Antibody Research Genome 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. These animals have been used as a key tool in functional genomics to generate models for human diseases and to validate new drugs.

Genetics 130

Genetics DNA Genome Genomics 130

The Pharma Data

DECEMBER 31, 2020

Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. About Twist Bioscience Corporation.

Antibody 52

Antibody DNA Containment Manufacturing 52

pharmaphorum

DECEMBER 5, 2022

The French biotech says VLA1553 met its objective in the phase 3 study, with 99% of patients exhibiting an antibody response against the virus 12 months after receiving a single dose of the shot, with no evidence of a tailing off in levels in the last six months. It will continue for up to five years.

Vaccine 98

Vaccine Vaccination Antibody Allergies 98

Pharmaceutical Technology

MARCH 9, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Pharmaceutical Technology

JULY 5, 2022

On leaving the liver cells, the virus hijacks bits of cell membrane and conceals itself from antibodies that would have isolated the virus before it travelled far through the bloodstream. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The LogicBio deal is the latest in a string of acquisitions for AstraZeneca.

Gene Editing 64

Gene Editing Gene Genome Genomics 64

The Pharma Data

DECEMBER 17, 2020

MacroGenics, a biopharma company working to make cancer history with the development of innovative monoclonal antibody-based therapeutics, had its first product , MARGENZA , approved by the FDA on Wednesday. The new two-hour infusion time was previously approved by the European Medicines Agency (EMA) in May 2020.

FDA Approval 52

FDA Approval Genome Genomics Production 52

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 147

Antibody Vaccine Vaccination Dermatology 147

Pharmaceutical Technology

AUGUST 26, 2008

“It has to be recognised that antibody therapy does not fit everyone and that small molecule therapy may be more appropriate for some people due to cost considerations.” “Biotechnology has exploded across the industry. “It also had good maturing capability. .” “It also had good maturing capability. .

Antibody 100

Antibody Licensing Licensing Production 100

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). Source link: [link].

Antibody 52

Antibody In-Vitro Trials Development 52

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Production Manufacturing Vaccine 130

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . From there, they evaluate what kind of antibodies are produced. ” The Application .

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

XTalks

JUNE 16, 2023

Cetuximab, an anti-epidermal growth factor receptor (anti-EGFR) antibody with FDA approval for metastatic colorectal cancer, is effective in conjunction with encorafenib. A negative result from a plasma specimen does not rule out genomic findings in a patient’s tumor. ” What is FoundationOne Liquid CDx?

FDA Approval 97

FDA Approval Genome Genomics DNA 97

pharmaphorum

SEPTEMBER 13, 2022

Further research led Ehrlich to develop his side-chain theory, that antibodies produced by white blood cells act as receptors on the cell membrane. 2012 – The 100,000 Genomics Project begins. Unlocking the secrets of the human genome has intrigued investigators for centuries. 2002 – Emergence of CAR-T therapy.

Genome Project 98

Genome Project Genome Genomics DNA 98

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. An ORR of 37% was reported for the overall trial population, with this increased to 62% in previously untreated patients.

Sales 147

Sales Trials FDA Approval Development 147

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. These sequences are usually silenced in healthy cells but are activated and presented on tumour cells.

Genome 80

Genome Genomics Licensing Licensing 80

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Antibody 52

Antibody Medicine In-Vitro Trials 52

XTalks

JANUARY 14, 2021

False negative results can occur with any molecular test, particularly if a mutation occurs in the part of the virus’s genome assessed by that test. However, it has a more concerning E484K mutation that may lower antibody recognition. So far, this does not appear to be the case for the N501Y mutation in the B.1.1.7.

Genetics 98

Genetics Genome Genomics Protein 98

pharmaphorum

JANUARY 24, 2023

The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100. The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

Delveinsight

JULY 30, 2020

Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody. The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. ‘Genome-tuning’ biotech Omega Therapeutics snags USD 85 Million. GlaxoSmithKline, the U.S.

Genome 52

Genome Genomics Antibody Gene 52

Pharmaceutical Technology

MAY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 130

Antibody DNA Genome Genomics 130

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

XTalks

SEPTEMBER 2, 2021

The AlzoSure Predict prognostic biomarker Alzheimer’s blood test detects levels of an unfolded conformational variant of the p53 protein in the blood using a proprietary antibody called U-p53AZ. It is known as the “guardian of the genome” given its central role in the DNA damage response. Diadem’s Alzheimer’s Blood Test.

Protein 105

Protein DNA Antibody Genome 105